Received Mar 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | 3004009 | — |
The patient took the third dose of Vivotif three days after the second dose; Case reference number US-BN-2024-002253 is a spontaneous case initially received from nurse via agency (reference number: USBAV24-1791) on 26-Jul-2024 and concerns an 18-year-old male patient. The patient's medical history and concomitant medication were not provided. On 21-Jul-2024, the patient took the first dose of Vivotif (batch number: 3004009), at an unknown dose or route, for immunization against disease caused by salmonella typhi. On 23-Jul-2024, two days after the first dose, the patient took the second dose of Vivotif (batch number: 3004009), at an unknown dose or route. On 26-Jul-2024, three days after the second dose, the patient took the third dose of Vivotif (batch number: 3004009), at an unknown dose or route (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Non-significant follow up was downloaded from VAERS on 09-May-2025 included new reference number Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240726-ff32e8 to US-BAVARIAN NORDIC A/S-US-BN-2024-002253, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: An 18-year-old male patient took the third dose of Vivotif for immunization against disease caused by salmonella typhi, on the day 3 after the second dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: An 18-year-old male patient took the third dose of Vivotif for immunization against disease caused by salmonella typhi, on the day 3 after the second dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.